Engineering Papers⌕ Search

SEARCH · Engineering Papers

Results for “Biosensors”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 343 records · Page 19
All sourcesNASA NTRSDOE OSTI
NASA NTRS2019

Carbon Nanomaterials for Biosensing Applications

Biosensing devices comprised of carbon nanotubes and nanofibers have been developed for astronaut crew point-of-care. Their inherent nanometer scale, high conductivity, wide potential window, good biocompatibility and well-defined surface chemistry make them ideal candidates as biosensor electrodes. Here, we report two studies using carbon nanotube and carbon nanofiber electrodes for biomedical applications. First, a 3x3 electrode device, with each electrode containing 40,000 carbon nanofiber nanoelectrodes was fabricated on silicon using traditional microfabrication processing. The device was demonstrated as a multiplexed immunosensor for simultaneous, label-free detection of cardiac troponin-I, C-reactive protein and myoglobin. Antibodies specific to cardiac troponin-I, C-reactive protein and myoglobin were covalently bound to the CNF surface and were characterized using electrochemical impedance spectroscopy and differential pulse voltammetry. Each step of the modification process resulted in changes in resistance to charge transfer due to the changes at the electrode surface upon antibody immobilization and binding to the specific cardiac protein. The real-time label free detection of the three cardiac markers from pure components and mixtures was demonstrated with high sensitivity, down to 0.2 ng/mL, and good selectivity. Detection in human blood serum did not present false positives from non-specific protein adsorption. More recently, this detection scheme has been applied to inkjet printed carbon nanotube electrodes on Kapton and paper. Printed devices have several unique advantages including simple and inexpensive fabrication. The results demonstrate that these sensors can serve a miniaturized, low cost device for detection of proteins in complex mixtures making this platform a good candidate for early stage diagnosis of myocardial infarction. Future inkjet printed devices can be fabricated have the added advantage in their suitability to be manufactured in an in-space, microgravity environment.

carbon nanotubes↗
NASA NTRS2014

Carbon Nanofiber Nanoelectrode Arrays for Neural Implant Devices

A sensor platform based on vertically aligned carbon nanofibers (CNFs) has been developed. Their inherent nanometer scale, high conductivity, wide potential window, good biocompatibility and well-defined surface chemistry make them ideal candidates as biosensor electrodes. Here, we report two studies using vertically aligned CNF nanoelectrodes for biomedical applications. CNF arrays are investigated as neural stimulation and neurotransmitter recording electrodes for application in deep brain stimulation (DBS). Polypyrrole coated CNF nanoelectrodes have shown great promise as stimulating electrodes due to their large surface area, low impedance, biocompatibility and capacity for highly localized stimulation. CNFs embedded in SiO2 have been used as sensing electrodes for neurotransmitter detection. Our approach combines a multiplexed CNF electrode chip, developed at NASA Ames Research Center, with the Wireless Instantaneous Neurotransmitter Concentration Sensor (WINCS) system, developed at the Mayo Clinic. Preliminary results indicate that the CNF nanoelectrode arrays are easily integrated with WINCS for neurotransmitter detection in a multiplexed array format. In the future, combining CNF based stimulating and recording electrodes with WINCS may lay the foundation for an implantable smart therapeutic system that utilizes neurochemical feedback control while likely resulting in increased DBS application in various neuropsychiatric disorders. In total, our goal is to take advantage of the nanostructure of CNF arrays for biosensing studies requiring ultrahigh sensitivity, high-degree of miniaturization, and selective biofunctionalization.

carbon nanotubes↗
NASA NTRS2020

Medical Data Architecture Prototype Development - Summary of Recent Work and Proposed Ideas for Upcoming Work

The Medical Data Architecture (MDA) project supports the Exploration Medical Capability (ExMC) risk to minimize or reduce the risk of adverse health outcomes and decrements in performance due to in-flight medical capabilities on human exploration missions. To mitigate this risk, the ExMC MDA project addresses the technical limitations identified in ExMC Gap Med 07: We do not have the capability to comprehensively process medically-relevant information to support medical operations during exploration missions, and in ExMC Gap Med 10: We do not have the capability to provide computed medical decision support during exploration missions. These gaps recognize the need for a comprehensive medical data management system and the accompanying computational support to provide autonomous medical care during long duration exploration missions. As the MDA matures—including the capability to comprehensively process and discover medically-relevant information to support medical operations during exploration missions—project focus will shift to maturing and extending the MDA platform to enable clinical decision support and real-time guidance. To date, the MDA foundational architecture has recommended exploration medical system Level of Care IV requirements through a series of test bed prototype developments and analog demonstrations. The next stage in the development will focus on more autonomous clinical decision making necessary to address challenges in executing a self-contained medical system that enables health care both with and without assistance from ground support. A thorough understanding of current state of medical decision support systems, advanced machine learning algorithms and vast and varied data sources is required. The development of a clinical decision support for exploration missions (Level of Care V) roadmap is needed: one that assesses of current state of the art of clinical decision support systems (CDSS), interoperability issues, identification of challenges in health and performance monitoring, obtaining and processing information from biosensors, knowledge and data management, data integration and fusion, and advanced algorithm development. This roadmap must also include rapid prototype development in the areas of data processing, advanced analysis and prediction of medical events, and treatment based on medically relevant information processing and evidence-based best practices. In this presentation, an overview of the relevant issues and the beginning framework of a Level of Care V CDSS development roadmap will be provided.

Krihak, M.↗
NASA NTRS2020

BioSentinel ISS Control Experiment Final Investigation Summary Form

Each payload has 18 fluidic cards and each fluidic card has 16 microfluidic wells, for a total of 288 wells. Card activation occurs at different time points throughout the 6-month mission and following ground commands. At each timepoint, two fluidic cards are filled with growth medium containing nutrients and a metabolic indicator dye. In addition to card filling, the temperature of the cards increases from ~4°C (stasis mode) to 23°C to allow for cell growth. The metabolic dye changes color from blue to pink, then pink to clearin the presence of metabolically active yeast cells. The colorimetric changes and cell growth are monitored using a 3-light-emitting diode(LED)optical detection system. The optical data determines how fast the cells are able to recover after accumulating radiation damage over time.After ground command initiation, all the fluidics, thermal and optical detection steps in BioSentinel are fully automated.The biosensor response data is compared to physical dosimetry data collected onboard the same payload. This dosimeter or linear energy transfer (LET)spectrometer is based on TimePix chip technology. This chip measures the total ionizing radiation dose in addition to calculating the LET of each particle that traverses its sensor, thus allowing researchers to characterize the radiation environment around the payload.The biological response (and physical dosimetry) on ISS over time is compared to the deep space mission and to data obtained on the ground.This analysis provides insight on the biological effects of the space radiation exposure in preparation for future long-duration missions to space and inhabitation beyond low-Earth orbit (LEO).

BioSentinel↗
NASA NTRSDate not supplied

Market Survey 2020: Commercial Clinical Decision Support Systems and Wellness Tools

For long-duration, deep space exploration missions, current methods for managing and supporting crew health and medical conditions will be unsuitable. Communication and data transmission lags will necessitate the use of a sophisticated clinical decision support system (CDSS) that will tailor diagnosis and treatment guidance that is context-sensitive for anticipated astronaut health, wellness, and medical conditions. A variety of clinical decision support (CDS) and wellness tools (WT) are currently available in the commercial market and a broad-brush survey of this market can provide an initial impression of the current state of the art which, in turn, can inform the roadmap of NASA deep space CDSS development and associated requirements. Such a survey was undertaken during the first six months of 2020 using directed convenience sampling to obtain information provided by vendors on their websites; both commercially available CDS and WT (such as those used to track and monitor nutrition, exercise, and sleep) were included. Areas assessed were item type (e.g., software/application, device); primary purpose of the item (e.g., diagnostic support, nutrition tracking); additional purposes (if any); reported features, capabilities, and functionality; setting of use (e.g., inpatient, outpatient); intended user (e.g., clinician, patient); location and sources of data/information used or produced by the item; integration with patient electronic health record (EHR); compliance with interoperability ontologies and standards (e.g., Health Level 7 [HL7], Systematized Nomenclature of Medicine – Clinical Terminology [SNOMED-CT]); and whether the item is knowledge-based (derived from research findings) or non-knowledge-based (derived through artificial intelligence, machine learning, advanced probability and statistics), among others. Ninety-seven (97) vendor websites describing 196 CDS and 73 WT (269 total) were reviewed and coded. The primary purpose of the majority of CDS reviewed is diagnosis or diagnosis/treatment/drug decision support—targeted for clinician use— and the primary purpose of the majority of WT reviewed is the monitoring of different health metrics, most often through the use of a biosensor device (e.g., blood pressure)—targeted for patient use. Very few CDS or WT appear to comply with major international interoperability standards or can be integrated with a patient’s EHR data. None consider contextual factors, such as conditions of the physical environment (e.g., CO2 levels). The majority of CDS and WT reviewed are non-knowledge, cloud- or web-based applications or software. Forty-three (43) major findings were identified and the implications those findings have for NASA will be discussed. Example major findings include: CDS-WT capabilities range from diagnosis to treatment applications, CDS-WT may be wearable or non-wearable and are technologically advanced and only a few CDS-WT tools referenced compliance to ensure interoperability, among other findings. Recommendations will also be offered that will help to address ExMC Gap, Medical-701: Enhance medical capabilities within an exploration medical system.

market survey↗
NASA NTRSDate not supplied

Printed Electrochemical Sensor for Quantifying Bone Density Loss in Microgravity

Printed electrochemical biosensors have been developed for astronaut point-of-care testing. Our fabrication approach is complimentary with in-space manufacturing for an on-demand and hands-free fabrication process. These sensors are developed using a combination of thin film materials printing and 3D printing and are comprised of carbon nanotube, gold nanoparticle, silver nanoparticle and dielectric inks to make traditional electrochemical sensor devices. Initial prototyped printed electrochemical sensors demonstrate good electrochemical performance while also displaying low batch to batch variability. Here we report the development of a printed sensor to monitor bone turnover. The absence of load bearing forces experienced in microgravity causes a reduction of overall bone mass and results in the development of space osteopenia/osteoporosis.(1,2) Our approach to identify space osteopenia/osteoporosis is to monitor the change in bone mass indirectly through an excreted biomarker of bone remodeling, amino-terminal collagen crosslinks (NTX). Antibodies specific to NTX are added to the sensor’s electrode ink and applied during the manufacturing process. NTX is measured from a urine sample by changes in voltammetry and electrochemical impedance as it binds to the antibody modified electrode surface. The measurement is rapid, quantitative and requires only small handheld electronics to perform the measurement. By this process, ground and flight physicians will receive frequent and real-time insight into the development of space osteopenia/osteoporosis to guide appropriate countermeasures. REFERENCES [1] Nabavi, N. et al (2011) Bone 49, 965-974. [2] Tamma, R. et al (2009) FASEB J 23, 2549-2554.

in-space manufacturing↗
NASA NTRSDate not supplied

Sweating the Small Stuff: A Sensor for Real-Time Neuro-Immune Axis Monitoring

Although manageable with certain precautions, circadian rhythm misalignment and sleep disturbances pose a potential threat to astronaut health. It is well-known that sleep is essential for proper immunological and neurological functioning, while impairments in these functions result in risks for spaceflight success. Neuropeptides and hormones are involved in regulating the circadian clock and are used as biomarkers for circadian alignment. However, in-flight monitoring of these biomarkers is limited due to the lack of real-time sensor systems and sample collection/processing confines. Therefore, real-time measurements of biomarkers in-flight are necessary for mission success and crew health. For this, a robust biomarker involved in the neuro-immune axis of circadian rhythm cycling, physiological stress responses, and inflammation would be well-received as a viable biomarker for assessing physiological health for crew during long-duration missions, as these are currently NASA Human Research Program defined risks. Therefore, this paper describes the development of a wearables we at biosensor to measure the biological clock neuropeptide, orexin/hypocretin. Additionally, potential for implementation of a user-friendly sensor of orexin/hypocretin to be telemetrically reported in real-time, is proposed. In brief, the proposed system has the possibility to be used as a biomarker monitor to support preventive and personalized medicine.

Amber M Paul↗
NASA NTRS2021

AIAA Ascend 2021 Conference On Demand Manufacturing of Electronics Panel Abstract

1. Session Proposal o Session Title NASA’s In Space Manufacturing and the On Demand Manufacturing of Electronics o Session Topic Primary -- Space Logistics, Autonomy, and Robotics; Secondary – Transformative Research and Technologies o Session Format: Panel Discussion. o Requested Session Duration: 60 minutes o Short Session Description: The goal of NASA’s On Demand Manufacturing of Electronics project is to develop and demonstrate the feasibility of a low-gravity, on-demand manufacturing system for flexible hybrid electronic devices on the International Space Station. This panel will feature several key collaborators and team members from the commercial sector, academia, and internal to NASA, each of which are contributing an unique and vital role to the design and implementation of this new technology system. o Extended Session Description (Please describe in detail the activity proposed, including how you intend to use the requested session duration. This session description will be provided to the reviewers for consideration and will not be displayed in the online agenda.): The session will be moderated by Curtis Hill, the Project Lead for the On Demand Manufacturing of Electronics (ODME), and he will start by giving a brief introduction to the ODME project which is working to produce a demo system for the manufacturing of electronic devices on the International Space Station. Panelists consisting of collaborators and team members to the ODME project will then give a brief (~5 min) introduction highlighting their contributions to the project, followed by time for Q&A from the audience. The panel will consist of: 1. Kenneth Church, nScrypt. nScrypt is a leader in multi-material printing with a modular system that incorporates a direct write thick film print head, a polymer fused filament fabrication print head, a laser sintering attachment, a drill head attachment for milling, and a pick and place. The system can print a layer and scan for accuracy of prints. The combination of multiple print heads and scanning allows for the on-demand production of intricate electronic components. 2. Andy Kurk, TechShot, Inc. Techshot, Inc. has collaborated extensively with NASA on the in space manufacturing of both printed electronics and fused metal materials. They are currently working to develop and integrate a test system for printed electronics, and a flight demonstration on the International Space Station is anticipated in 2024. 3. Ed Hendricks, NextFlex. NextFlex has the goal of advancing the manufacture of flexible hybrid electronics in the U.S. They are working with ODME on the development of AstroSense, an additively manufactured, wireless, flexible, and wearable health sensor. 4. Dr. Pradeep Lall, Auburn University. Professor Lall is the MacFarlane Endowed Distinguished Professor in the Department of Mechanical Engineering with a Courtesy Joint Appointment in the Department of Electrical and Computer Engineering and a Courtesy Joint Appointment in the Department of Finance. He is collaborating with NASA’s ODME project to develop multilayer printable devices and to develop techniques to test the quality of a printed electronic device. 5. Dr. Wei Gao, California Institute of Technology. Professor Gao is an Assistant Professor of Medical Engineering. His group is developing fully printed, flexible, and wearable biosensors for crew health monitoring in collaboration with NASA’s ODME project. In addition, they are working on using sweat to power biofuel cells for wearable, self-powered electronic devices. 6. Beth Paquette, NASA Goddard. The ODME branch at NASA Goddard is spearheading a sounding rocket flight demo to prove the capability of a printed electronic device with multiple sensors. In addition, they focus on thin film and flexible energy storage evaluations. o Session Goal(s)/Outcome(s): Please list the learning objectives and/or tangible outcomes (technical paper or other publication). The goal of this session is to highlight the internal and collaborative efforts of NASA’s On Demand Manufacturing of Electronics project to develop a system for printing electronics that will be tested on the International Space Station in 2024. In addition, the session with facilitate discussion with the community on the state of the art of printable electronics, current challenges, and new avenues for collaboration.

Jennifer McInnis Jones↗
NASA NTRSDate not supplied

BioSentinel: To the Moon or Beyond?

BioSentinel, an Artemis-1 secondary spacecraft, will carry a biology experiment into deep space for the first time in 50 years. A 6U CubeSat form factor was utilized for the spacecraft and included technologies newly developed or adapted for operations beyond Earth orbit. This is the maiden deep-space voyage for the radio, propulsion system, electrical power system, and BioSensor payload. The spacecraft carries onboard budding yeast, Saccharomyces cerevisiae, as an analog to human cells to test the biological response to deep space radiation. Flying a secondary payload beyond LEO comes with unique challenges with respect to trajectory uncertainty and mission operations planning. BioSentinel does not carry propulsion for trajectory maneuvers, so plans for Comms and Power need to be developed for all trajectories. The nominal plan is a lunar flyby followed by an insertion into Heliocentric orbit. However, some possible scenarios include lunar eclipses that could severely impact the power budget during that phase of the mission, while others could result in a “Retrograde” hyperbola at swingby resulting in the spacecraft traveling inward toward Earth or even towards a collision with the lunar surface. BioSentinel’s final trajectory will not be known until after launch and deployment so possible scenarios need to be planned for ahead of time. This paper discusses the operational scenarios that were planned for as well as the actual execution of the mission operations including: command pass scheduling with the Deep Space Network, selecting bandwidth limits, medium gain antenna versus low gain antenna usage, and conserving power prior to a lunar eclipse. Note: Artemis-1 is planned to launch in the Spring of 2022

BioSentinel↗
NASA NTRSDate not supplied

BioSentinel: NASA’s First Deep Space Biological Mission

Since Apollo 17 in 1972, NASA has sent no humans or other biological organisms outside of Earth’s protective magnetosphere. NASA’s current Artemis program plans to put astronauts back on the Moon and eventually land human missions on Mars. One of the major challenges to long-duration crewed travel and habitation in deep space is an in-depth understanding of the biological effects of space radiation, often convoluted by the impact of reduced gravity. Such missions will require significant countermeasures, likely both technological and biomedical, to protect organisms from chronic radiation exposure. Small satellite missions like CubeSats can inform these countermeasures by investigating model organisms in relevant space environments. The BioSentinel mission is comprised of four segments developed at NASA Ames Research Center: a 6U CubeSat (1U = 10-cm cube), an ISS payload launched in December 2021 and two ground units, one for the mission’s CubeSat and one for the ISS payload. The last three segments have been operational since January 2022 and serve as experimental controls. BioSentinel’s 6U CubeSat is planned to launch as a secondary payload on the Artemis-1 rocket. It will be deployed on a lunar fly-by trajectory and into a heliocentric orbit. BioSentinel will be the first interplanetary satellite to study the biological response to space radiation outside Low Earth Orbit (LEO) in almost 50 years. BioSentinel is a complete, autonomous spacecraft capable of conducting experiments in deep space. Its 4U BioSensor payload is a fully automated and adaptable platform that can perform biological measurements with a range of microorganisms in multiple space environments, including the ISS, free flyers, and other platforms like the Lunar Gateway and lander vehicles. Once it reaches its orbit, BioSentinel’s CubeSat will measure the DNA damage response to ambient radiation in a model organism, the budding yeast Saccharomyces cerevisiae, which will be compared to information provided by an onboard radiation sensor and to data obtained in LEO (on ISS) and on Earth. Once in interplanetary space, fluidic cards containing desiccated yeast will be activated by growth medium addition at different time points throughout the mission. Growth and metabolic activity will be tracked continuously via optical measurements. This paper describes BioSentinel’s objectives, science, data management, and preliminary results from the ISS and ISS ground control segments.

BioSentinel↗
NASA NTRSDate not supplied

BioSentinel SmallSat 2022 Presentation

BioSentinel, an Artemis-1 secondary spacecraft, will carry a biology experiment into deep space for the first time in 50 years. A 6U CubeSat form factor was utilized for the spacecraft and included technologies newly developed or adapted for operations beyond Earth orbit. This is the maiden deep-space voyage for the radio, propulsion system, electrical power system, and BioSensor payload. The spacecraft carries onboard budding yeast, Saccharomyces cerevisiae, as an analog to human cells to test the biological response to deep space radiation.

BioSentinel↗
NASA NTRSDate not supplied

BioSentinel: NASA’s First Deep Space Biological Mission

Since Apollo 17 in 1972, NASA has sent no humans or other biological organisms outside of Earth’s protective magnetosphere. NASA’s current Artemis program plans to put astronauts back on the Moon and eventually land human missions on Mars. One of the major challenges to long-duration crewed travel and habitation in deep space is an in-depth understanding of the biological effects of space radiation, often convoluted by the impact of reduced gravity. Such missions will require significant countermeasures, likely both technological and biomedical, to protect organisms from chronic radiation exposure. Small satellite missions like CubeSats can inform these countermeasures by investigating model organisms in relevant space environments. The BioSentinel mission is comprised of four segments developed at NASA Ames Research Center: a 6U CubeSat (1U = 10-cm cube), an ISS payload launched in December 2021 and two ground units, one for the mission’s CubeSat and one for the ISS payload. The last three segments have been operational since January 2022 and serve as experimental controls. BioSentinel’s 6U CubeSat is planned to launch as a secondary payload on the Artemis-1 rocket. It will be deployed on a lunar fly-by trajectory and into a heliocentric orbit. BioSentinel will be the first interplanetary satellite to study the biological response to space radiation outside Low Earth Orbit (LEO) in almost 50 years. BioSentinel is a complete, autonomous spacecraft capable of conducting experiments in deep space. Its 4U BioSensor payload is a fully automated and adaptable platform that can perform biological measurements with a range of microorganisms in multiple space environments, including the ISS, free flyers, and other platforms like the Lunar Gateway and lander vehicles. Once it reaches its orbit, BioSentinel’s CubeSat will measure the DNA damage response to ambient radiation in a model organism, the budding yeast Saccharomyces cerevisiae, which will be compared to information provided by an onboard radiation sensor and to data obtained in LEO (on ISS) and on Earth. Once in interplanetary space, fluidic cards containing desiccated yeast will be activated by growth medium addition at different time points throughout the mission. Growth and metabolic activity will be tracked continuously via optical measurements. This paper describes BioSentinel’s objectives, science, data management, and preliminary results from the ISS segment.

BioSentinel↗
NASA NTRS2022

Evolution of Biological Satellites: From Low Earth Orbit to NASA’s BioSentinel Deep Space Mission

NASA has set its sights on human exploration in deep space with the Artemis missions, with an ambitious plan to put astronauts back on the Moon and to eventually land human missions on Mars. Such missions will require significant countermeasures, likely both technological and biomedical, to protect biology from chronic radiation exposure. Small satellites like CubeSats can inform these countermeasures by querying relevant space environments with model organisms over relevant durations. NASA has launched five biological CubeSats into low Earth orbit (LEO) from GeneSat in 2006 to EcAMSat in 2017. Each one of these missions increased our understanding of the effects of spaceflight, while refining technologies and imparting valuable lessons to the next generation of CubeSats. The Artemis I rocket will carry ten CubeSats, each of them with its own objective. One in particular, BioSentinel, will conduct the first study of the biological response to interplanetary space radiation beyond LEO since Apollo 17. Once it reaches its heliocentric orbit – after a short lunar fly-by – BioSentinel will measure the DNA damage response to ambient radiation in a model organism, the budding yeast Saccharomyces cerevisiae, which will be compared to information provided by an onboard radiation sensor and to data obtained in LEO (on ISS) and on Earth. Once in interplanetary space, fluidic cards containing desiccated yeast cells will be activated by growth medium addition at different time points throughout the mission. Growth and metabolic activity will be tracked continuously via optical density. BioSentinel is a complete, autonomous spacecraft capable of conducting experiments in deep space. Its 4U BioSensor payload is a fully automated and adaptable platform that can perform biological measurements with a range of microorganisms in multiple space environments, including the ISS, free flyers, and other platforms like the Lunar Gateway and lander vehicles.

Sergio R Santa Maria↗
NASA NTRSDate not supplied

BioSentinel: Mission Summary and Lessons Learned From the First Deep Space Biology CubeSat Mission

Launched on Artemis-1, BioSentinel carries a biology experiment into deep space for the first time in 50 years. A 6U CubeSat form factor was utilized for the spacecraft which included technologies newly developed or adapted for operations beyond Earth orbit. The spacecraft carries onboard budding yeast, Saccharomyces cerevisiae, as an analog to human cells to test the biological response to deep space radiation. This was the maiden deep-space voyage for many of the subsystems, and the first time to evaluate their performance in flight operation. Flying a CubeSat beyond LEO comes with unique challenges with respect to trajectory uncertainty and mission operations planning. The nominal plan was a lunar fly-by, followed by an insertion into Heliocentric orbit. However, some possible scenarios included lunar eclipses that could have severely impacted the power budget during that phase of the mission, while others could have resulted in a “Retrograde” hyperbola at swing-by resulting in the spacecraft traveling inward toward Earth or even towards a collision with the lunar surface. The commissioning phase of the mission was successful and completed a week ahead of schedule. It did not come without its exciting moments and challenges. First contact with the spacecraft uncovered that the vehicle was unexpectedly tumbling after deployment, a situation that needed to be corrected urgently. The mission operations team executed a contingency plan to stabilize the spacecraft, with just moments to spare before the battery ran out of power. The BioSensor payload onboard the spacecraft is a complex instrument that includes microfluidics, fluid systems, sensor control electronics, as well at the living yeast cells. BioSentinel also included a TimePix radiation sensor implemented by JSC’s RadWorks group. Dose and Linear Energy Transfer (LET) data is compared directly to the rate of DSB-and repair events measured by the S. cerevisiae cells. BioSentinel mature nanosatellite technologies included: deep space communications and navigation, autonomous attitude control and momentum management, and micro-propulsion systems, to provide an adaptable nanosatellite platform for deep space uses. This paper discusses the performance of the BioSentinel spacecraft through the mission phase, and includes lessons learned from challenges and anomalies. BioSentinel had many successes and will be a pathfinder for future deep space CubeSats and biology missions.

BioSentinel↗
NASA NTRSDate not supplied

NASA SmallSat LEARN Forum Briefing: BioSentinel

We will focus on the technologies developed for BioSentinel, primarily the science payloads. One of them, the BioSensor, is a microfluidics-based instrument that houses a series of fluidic cards and manifolds. The fluidic cards can be loaded with microbial organisms to study the effect of the space environment on biology. For BioSentinel, we used the budding yeast as our model organism to study the response to the radiation environment in both low Earth orbit (ISS) and in deep space. The second instrument is a radiation spectrometer. This sensor allows the quantification of ionizing radiation as well as the characterization of the different particles based on the linear energy transfer or LET. Given that BioSentinel launched this past November (Artemis I), part of the presentation will include lessons learned and how we will apply them to future missions, including LEIA. LEIA was recently selected for a mission to the lunar surface on a CLPS lander vehicle, and is primarily based at NASA Ames.

BioSentinel↗
NASA NTRSDate not supplied

Biosentinel: Mission Summary and Lessons Learned From the First Deep Space Biology CubeSat Mission

Launched on Artemis-1, BioSentinel carries a biology experiment into deep space for the first time in 50 years. A 6U CubeSat form factor was utilized for the spacecraft which included technologies newly developed or adapted for operations beyond Earth orbit. The spacecraft carries onboard budding yeast, Saccharomyces cerevisiae, as an analog to human cells to test the biological response to deep space radiation. This was the maiden deep-space voyage for many of the subsystems, and the first time to evaluate their performance in flight operation. Flying a CubeSat beyond LEO comes with unique challenges with respect to trajectory uncertainty and mission operations planning. The nominal plan was a lunar fly-by, followed by an insertion into Heliocentric orbit. However, some possible scenarios included lunar eclipses that could have severely impacted the power budget during that phase of the mission, while others could have resulted in a “Retrograde” hyperbola at swing-by resulting in the spacecraft traveling inward toward Earth or even towards a collision with the lunar surface. The commissioning phase of the mission was successful and completed a week ahead of schedule. It did not come without its exciting moments and challenges. First contact with the spacecraft uncovered that the vehicle was unexpectedly tumbling after deployment, a situation that needed to be corrected urgently. The mission operations team executed a contingency plan to stabilize the spacecraft, with just moments to spare before the battery ran out of power. The BioSensor payload onboard the spacecraft is a complex instrument that includes microfluidics, fluid systems, sensor control electronics, as well at the living yeast cells. BioSentinel also included a TimePix radiation sensor implemented by JSC’s RadWorks group. Dose and Linear Energy Transfer (LET) data is compared directly to the rate of DSB-and repair events measured by the S. cerevisiae cells. BioSentinel mature nanosatellite technologies included: deep space communications and navigation, autonomous attitude control and momentum management, and micro-propulsion systems, to provide an adaptable nanosatellite platform for deep space uses. This paper discusses the performance of the BioSentinel spacecraft through the mission phase, and includes lessons learned from challenges and anomalies. BioSentinel had many successes and will be a pathfinder for future deep space CubeSats and biology missions.

BioSentinel↗
NASA NTRSDate not supplied

Microbial Vessel for Impedance Spectroscopy and Electrochemistry (Mvise): an Extensible, Interoperable Data Acquisition Platform for Liquid Culture Studies in Space Biology Research

The White House Office of Science and Technology Policy (OSTP) has declared 2023 to be the Year of Open Science following an initiative to democratize scientific knowledge. Simultaneously, new sensor technologies have broadened the experimental space available to bioastronautics research. With these open-science goals and technological advances in mind, we have designed and constructed a data acquisition platform for high-precision, real-time monitoring of liquid culture systems. The vessel rig is fitted with six Atlas Scientific probes (micro pH, electrical conductivity, dissolved oxygen, oxidation-reduction potential, liquid temperature, air CO2) and a custom optical density probe similar to the one on BioSentinel’s BioSensor payload. A custom dielectric spectroscopy probe is also planned. The structure of the vessel is resin 3-D printed on a hobbyist-level machine, reducing the production cost and iteration time by over 60% each while increasing extensibility. Data acquisition and storage is controlled with a standalone C state machine-based program running on a Raspberry Pi 3 Model B. When not running headless, an additional program automatically generates and updates plots for live data visualization. Validation of the rig as a data collection system was performed with a yeast liquid culture experiment. While the vessel rig is currently used for standalone experiments, it can also be used as the base perception unit in a self-driving laboratory (SDL). SDLs are high-throughput data collection systems that employ automation and artificial intelligence to conduct and manage routine experiments. Here, we envision an SDL driven by several vessel rigs in which an automated script compares key results, informing the design of future experiments. A vessel rig SDL would streamline many operations, including 1) strain selection for the Lunar Explorer Instrument for space biology Applications (LEIA) investigation and 2) the study of bioregenerative life support systems (BLSS). Ultimately, the datasets that can now be acquired will provide crucial information for accelerating bioastronautics application development in the era of commercial space.

Stephen Lantin↗
NASA NTRSDate not supplied

Biosentinel: The First Deep Space Biology CubeSat Mission- Mission Summary and Lessons Learned

Launched on Artemis-1, BioSentinel carries a biology experiment into deep space for the first time in 50 years. A 6U CubeSat form factor was utilized for the spacecraft which included technologies newly developed or adapted for operations beyond Earth orbit. The spacecraft carries onboard budding yeast, Saccharomyces cerevisiae, as an analog to human cells to test the biological response to deep space radiation. This was the maiden deep-space voyage for many of the subsystems, and the first time to evaluate their performance in flight operation. Flying a CubeSat beyond LEO comes with unique challenges with respect to trajectory uncertainty and mission operations planning. The nominal plan was a lunar fly-by, followed by an insertion into Heliocentric orbit. However, some possible scenarios included lunar eclipses that could have severely impacted the power budget during that phase of the mission, while others could have resulted in a “Retrograde” hyperbola at swing-by resulting in the spacecraft traveling inward toward Earth or even towards a collision with the lunar surface. The commissioning phase of the mission was successful and completed a week ahead of schedule. It did not come without its exciting moments and challenges. First contact with the spacecraft uncovered that the vehicle was unexpectedly tumbling after deployment, a situation that needed to be corrected urgently. The mission operations team executed a contingency plan to stabilize the spacecraft, with just moments to spare before the battery ran out of power. The BioSensor payload onboard the spacecraft is a complex instrument that includes microfluidics, fluid systems, sensor control electronics, as well at the living yeast cells. BioSentinel also included a TimePix radiation sensor implemented by JSC’s RadWorks group. Dose and Linear Energy Transfer (LET) data is compared directly to the rate of DSB-and repair events measured by the S. cerevisiae cells. BioSentinel mature nanosatellite technologies included: deep space communications and navigation, autonomous attitude control and momentum management, and micro-propulsion systems, to provide an adaptable nanosatellite platform for deep space uses. This paper discusses the performance of the BioSentinel spacecraft through the mission phase, and includes lessons learned from challenges and anomalies. BioSentinel had many successes and will be a pathfinder for future deep space CubeSats and biology missions.

BioSentinel↗